You are here

Clinical trial proves efficacy of Bioiberica’s Atopivet® Spot-On in dogs with atopic dermatitis

7 Apr 2020
Companion Animal Health
  • The study, carried out at the University of Florida, supports the use of this new formulation of sphingolipids and glycosaminoglycans as a strategy to improve skin health in patients with canine atopic dermatitis

Bioiberica Companion Animal Health and the University of Florida have published the results of a clinical study in dogs with atopic dermatitis that confirms the efficacy of the Atopivet® Spot-On topical formulation to help restore skin barrier function, hydrate skin and reduce itching, as a monotherapy or part of a multimodal treatment. The study, titled Topical treatment with sphingolipids and glycosaminoglycans for canine atopic dermatitis, is available in the open-access scientific journal BMC Veterinary Research.

It was a prospective, double-blinded, controlled clinical trial conducted on twelve dogs with induced atomic dermatitis randomly allocated to two groups: control and treatment. The dogs in the control group did not receive any intervention, while dogs in the treatment group were administered Bioberica Atopivet® Spot-On, which contains 0.5% of a sphingomyelin-rich sphingolipid extract (Biosfeen®) and 0.5% of a hyaluronic acid-rich glycosaminoglycan extract (Dermial®) as its active ingredients.

The product was administered topically twice a week for 8 weeks, on the pinnae, axilla, interdigital areas of front and back paws, inguinal area, chest and dorsum.

“Clinical results after topical administration of sphingolipids and glycosaminoglycans, especially regarding pruritus, confirm the efficacy of this new combination in treating canine atopic dermatitis. It is important to note that the dogs were not given any other treatment, which indicates a notable benefit of Atopivet® Spot-On,” explains Dr Sergi Segarra, R&D Project Manager Human & Animal Health at Bioiberica.

Canine atopic dermatitis: common and chronic

Canine atopic dermatitis is a genetically predisposed inflammatory and pruritic skin disease common in dogs (10%-15% of the population) with characteristic clinical features associated with IgE antibodies most commonly directed against environmental allergens, as described at the US National Library of Medicine National Institutes of Health (NIH).

The most common sign of the disease is pruritus of the skin from constant scratching, licking or rubbing.

Diagnosis of atopic dermatitis means diagnosing a chronic disease that will require treatment and care throughout the animal’s life.

 

References:

Marsella, R., Segarra, S., Ahrens, K., Alonso, C., Ferrer, L. (2020). Topical treatment with sphingolipids and glycosaminoglycans for canine atopic dermatitis.BMC Vet Res, 16, 92 (2020). doi: https://doi.org/10.1186/s12917-020-02306-6

Related News

25 Jan 2021
Companion Animal Health
  • The product is a supplementary food recommended to nurture growing joints in puppies, principally for fast-growing large breeds and in breeds predisposed to hip dysplasia
  • This is the third launch for the joint health area in the last three years, which renews the entire line.
30 Nov 2020
Companion Animal Health
  • This dietary supplement is recommended to protect the joints of large dog breeds
  • The product stands out for its great palatability, convenient dosage and unique composition on the market
14 Sep 2020
Companion Animal Health
  • This completes its Atopivet® range of dermatological products, both orally and topically, which help maintain the skin's integrity and protective barrier
  • There is increasing evidence that shows that the epidermal barrier function is impaired in canine atopic dermatitis